Form 4: Novavax Executive Filip Dubovsky Reports Stock Option Exercise and Sale

Filip Dubovsky, President of R&D at Novavax, exercised stock options and sold shares on June 17, 2024, according to a Form 4 filing.

Summary

• Filip Dubovsky, President of R&D at Novavax, filed a Form 4 detailing changes in beneficial ownership of Novavax stock.
• On June 17, 2024, Dubovsky exercised stock options to acquire 1,404 shares at $6.97 and 12,500 shares at $6.09.
• Simultaneously, Dubovsky sold 12,500 shares at $14.46 and 1,404 shares at $14.54.
• Following these transactions, Dubovsky directly owns 66,613 shares of Novavax common stock.
• Dubovsky also holds options to purchase 46,324 shares at $6.97 and 37,500 shares at $6.09.

Sentiment

Score: 5

Explanation: This is a routine Form 4 filing, reflecting standard executive compensation practices. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

Executive stock transactions are common and are closely watched by investors for signals about a company's prospects. Option exercises and sales can be driven by various factors, including personal financial planning.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.

Key Dates